Harbour BioMed and Pharmaceutical Product Development, LLC (PPD) entered a strategic collaboration to develop HBM’s therapeutics in the fields of oncology and immunology.
 
HBM and PPD recently completed an Australian ethics committee (EC) submission for HBM4003, an anti-cancer immunotherapyto target solid tumors. The companies achieved the key milestone ahead of schedule, on the path to Phase I trials in Australia and the U.S.
  
"As a rapidly growing, medium-sized biotech company with global operations, we value the way PPD’s global capabilities and biotech-friendly approach both complement and extend our team’s decades of expertise in running global trials," said Jingsong Wang, M.D., Ph.D., founder, chairman and chief executive officer of HBM. "I’m pleased that our collaborative partnership already has enabled us to achieve the important milestone of our first global EC submission, and ahead of our aggressive schedule. We look forward to entering the clinical trial phase of our development programs with PPD as we pursue our global vision and ambition of delivering next-gen therapeutics to fulfill patient needs around the world."
  
"Our enthusiasm for the opportunity to support the development of HBM’s innovative assets is equaled by our shared commitment to helping accelerate the delivery of life-changing therapies to patients," said Anshul Thakral, executive vice president and global head of PPD Biotech. "We believe pairing an innovative biotech mindset with our scalable global development services is a powerful combination for our customers."

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.